MARKET

CFRX

CFRX

Contrafect Corp
NASDAQ
0.1298
+0.0007
+0.54%
After Hours: 0.1282 -0.0016 -1.23% 19:40 12/08 EST
OPEN
0.1300
PREV CLOSE
0.1291
HIGH
0.1387
LOW
0.1251
VOLUME
1.25M
TURNOVER
0
52 WEEK HIGH
4.540
52 WEEK LOW
0.1251
MARKET CAP
5.11M
P/E (TTM)
-0.0855
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 1d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 2d ago
CFRX: Cleared to Begin Clinical Trial for Exebacase in Chronic Prosthetic Joint Infection…
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Approval to Initiate Clinical Trial for Exebacase in Chronic Knee Prosthetic Joint Infections On November 28, 2022, ContraFect Corp. (NASDAQ:CFRX) announced that ANSM, the F...
Zacks Small Cap Research · 11/30 13:34
Why Elbit Systems Shares Are Trading Lower By Over 10%; Here Are 24 Stocks Moving Premarket
Benzinga · 11/29 12:28
ContraFect Announces ANSM Approval Of Clinical Trial Application For Exebacase In Prosthetic Joint Infections
Benzinga · 11/28 13:10
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 11/28 13:09
ContraFect Says French Regulator Approves Trial Application for Exebacase to Treat Prosthetic Joint Infection of Knee
ContraFect Says French Regulator Approves Trial Application for Exebacase to Treat Prosthetic Joint Infection of Knee
MT Newswires · 11/28 09:29
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/23 13:07
More
About CFRX
ContraFect Corporation is a late clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa and has demonstrated potent in vivo activity against extensively drug-resistant (XDR) strains. It has developed an, engineered variant of exebacase, known as CF-296. It is conducting further in vitro and in vivo characterization of CF-296 to evaluate the full profile of this compound.

Webull offers kinds of ContraFect Corp stock information, including NASDAQ:CFRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CFRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CFRX stock methods without spending real money on the virtual paper trading platform.